March 30, 2020

CB2 Insights Launches Industry’s First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders

Free interactive tool allows industry players to gain immediate insights derived from CB2 Insights aggregated and anonymized clinical outcome data.
January 29, 2020

CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors

CB2 Insights is pleased to announce the appointment of Tom Brogan, as an independent director to CB2’s Board of Directors.
January 28, 2020

CB2 Insights Announces Completion of Payment of New Jersey Alternative Medicine

CB2 Insights announces it has completed all payment obligations for the June 2019 acquisition of New Jersey Alternative Medicine.
January 14, 2020

CB2 Insights Selected by Vireo Health to Support Medical Cannabis Clinical Trial

Partnership Underway to Develop Extensive Protocols and Submissions for US Food & Drug Administration to Uncover Safety and Efficacy for...
December 16, 2019

CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)

CB2 Insights announced that it will begin a prospective trial with GL Brands through its hemp brand and key operating...
December 12, 2019

CB2 Insights Completes Full-Scale Platform to Connect Disparate Data Systems

CB2 Insights announced its core technology platform, Sail, is now primed for streamlining and aggregating disparate healthcare data systems.
December 11, 2019

CB2 Insights Launches Warrant Incentive Program

CB2 Insights announces a warrant exercise incentive program which has been implemented to encourage the exercise of the Company’s outstanding...